Want to see SE:BIOA.B full AI Analyst Report?
BioArctic AB Class B (BIOA.B) AI Stock Analysis
BioArctic AB Class B
(Nasdaq OMX AB:BIOA.B)
The overall score of 62 reflects a company with a fortress-like, debt-free balance sheet that is offset by a sharp deceleration in revenue and cash flow growth, and an extremely demanding valuation. The primary strength is the company's pristine financial position, which provides significant stability. The most significant risks are the 12.6% TTM revenue decline and a P/E ratio of 135, which prices the stock for perfection at a time when fundamentals are weakening. The neutral technical picture does little to sway the score in either direction.
BioArctic AB Class B (BIOA.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 28.15B
- Dividend Yield
- 0.68%
- Average Volume (3M)
- 138.80K
- Price to Earnings (P/E)
- 266.6
- Beta (1Y)
- 0.42
- Revenue Growth
- -46.09%
- EPS Growth
- -90.13%
- Country
- Sweden
- Employees
- 150
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
BioArctic AB Class B Business Overview & Revenue Model
Company Description
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The compa...
How the Company Makes Money
BioArctic primarily makes money through partnering and licensing its drug programs to larger pharmaceutical companies that fund significant parts of clinical development, regulatory work, and commercialization. Key revenue streams typically include:...
BioArctic AB Class B Financial Statement Overview
Summary
BioArctic's financial health is a tale of two periods. The balance sheet is exceptional, with virtually no debt and a rapidly growing equity base, earning a score of 88. However, the income statement (72) and cash flow (65) scores reveal a significant recent slowdown, with TTM revenue declining 12.6% and free cash flow growth collapsing. The overall financial picture is of a highly profitable, debt-free company that has likely passed its peak earnings cycle, warranting caution.
Income Statement
72PositiveBalance Sheet
88Very PositiveCash Flow
65Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.00B | 2.00B | 257.35M | 616.00M | 228.29M | 23.15M |
| Gross Profit | 933.97M | 1.94B | 230.37M | 526.37M | 153.97M | -31.92M |
| EBITDA | 227.69M | 1.38B | -176.95M | 295.29M | 3.58M | -126.63M |
| Net Income | 105.52M | 1.02B | -177.08M | 229.25M | -11.18M | -119.79M |
Balance Sheet | ||||||
| Total Assets | 2.82B | 2.58B | 1.11B | 1.19B | 858.31M | 897.73M |
| Cash, Cash Equivalents and Short-Term Investments | 1.99B | 2.19B | 778.92M | 1.11B | 805.39M | 848.40M |
| Total Debt | 90.61M | 44.07M | 54.23M | 4.98M | 10.04M | 15.88M |
| Total Liabilities | 802.78M | 608.14M | 216.74M | 139.50M | 72.06M | 109.05M |
| Stockholders Equity | 2.02B | 1.97B | 894.94M | 1.05B | 786.24M | 788.68M |
Cash Flow | ||||||
| Free Cash Flow | 106.14M | 1.42B | -342.97M | 302.25M | -44.38M | -144.84M |
| Operating Cash Flow | 243.98M | 1.43B | -316.33M | 309.69M | -31.64M | -140.46M |
| Investing Cash Flow | 42.30M | -894.65M | 205.63M | -507.49M | -12.76M | -4.41M |
| Financing Cash Flow | -153.68M | 26.91M | 5.69M | 14.06M | -2.81M | -7.39M |
BioArctic AB Class B Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOA.B, the sentiment is Positive. The current price of 310.20 is above the 20-day moving average (MA) of 300.76, below the 50-day MA of 313.90, and below the 200-day MA of 316.11, indicating a bullish trend. The MACD of 1.30 indicates Negative momentum. The RSI at 58.85 is Neutral, neither overbought nor oversold. The STOCH value of 83.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOA.B.
BioArctic AB Class B Peers Comparison
Overall Rating
SE:SANION77Outperform- SE:BIOA.B62Neutral
SE:ALZCUR55Neutral
SE:BINV47Neutral
SE:IRLAB.A46Neutral
SE:ALZ43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:SANION | 77Outperform | SEK 1.54B | 8.30 | 29.71% | ― | 24.98% | -31.44% |
| SE:BIOA.B | 62Neutral | SEK 28.15B | 266.55 | 5.18% | 0.68% | -46.09% | -90.13% |
| SE:ALZCUR | 55Neutral | SEK 882.54M | 42.87 | 65.99% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:BINV | 47Neutral | SEK 357.32M | -0.73 | -128.54% | ― | -83.67% | -50.29% |
| SE:IRLAB.A | 46Neutral | SEK 310.81M | -3.21 | -97.06% | ― | 4.74% | 66.33% |
| SE:ALZ | 43Neutral | SEK 112.04M | -1.68 | -17.52% | ― | -100.00% | 20.94% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:BIOA.B | BioArctic AB Class B | 317.20 | 34.68 | 12.27% | |
| SE:BINV | BioInvent International AB | 5.43 | -27.72 | -83.62% | |
| SE:ALZ | Alzinova AB | 0.35 | -1.07 | -75.14% | |
| SE:ALZCUR | AlzeCure Pharma AB | 6.40 | 4.54 | 243.16% | |
| SE:SANION | Saniona AB | 11.13 | -5.17 | -31.72% | |
| SE:IRLAB.A | IRLAB Therapeutics AB Class A | 2.09 | -0.27 | -11.37% |
BioArctic AB Class B Corporate Events
BioArctic’s Leqembi Begins First Real-World Use in Sweden After EU Approval
BioArctic AB said that Leqembi, its Alzheimer’s drug developed with Eisai, has become available at a private clinic in Sweden, where the first patient outside a clinical study has now started treatment since the therapy’s EU approval in 2...
Japan Approves At-Home Leqembi Pen for Early Alzheimer’s Treatment
Eisai, BioArctic’s partner in Alzheimer’s therapeutics, has secured Japanese approval for Leqembi Pen, a subcutaneous autoinjector formulation of lecanemab for early Alzheimer’s disease. The new route complements the existing intrav...
BioArctic Partner Eisai Wins China Approval for At-Home Leqembi Alzheimer’s Autoinjector
BioArctic’s partner Eisai has secured approval from China’s National Medical Products Administration for the Leqembi subcutaneous autoinjector formulation as an initiation treatment for patients with mild cognitive impairment or mild deme...
BioArctic’s Leqembi Wins Key Canadian Reimbursement Backing
BioArctic’s partner Eisai has secured a final positive recommendation from Canada’s Drug Agency supporting public reimbursement of Leqembi for eligible patients with mild cognitive impairment or mild dementia due to early Alzheimer’...
BioArctic Updates Share and Vote Structure After Stock Option Exercise
BioArctic AB has slightly expanded its share capital following the issuance of 20,200 Class B shares in August 2026 to fulfill obligations under its long-term stock option program adopted in 2019. The move reflects the ongoing use of equity-based inc...
BioArctic Deepens Alzheimer’s Footprint With Leqembi Expansion and New Strategic Alliances
BioArctic reported second-quarter 2026 net revenues of SEK 247.5 million, with royalty income from Alzheimer’s drug Leqembi rising to SEK 179.4 million, but posted a small operating loss amid heavy R&D spending that accounted for 73% of ope...
BioArctic and Eisai Expand At-Home Alzheimer’s Treatment With U.S. Launch of Leqembi Iqlik
BioArctic’s partner Eisai has launched Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab, in the U.S. for initiation therapy in early Alzheimer’s disease, offering at-home dosing for both initiation and maintenance. The...
BioArctic and Mesenkia team up on novel glioblastoma therapy
BioArctic and Mesenkia Therapeutics have entered a research collaboration to develop a novel antibody-based treatment approach for glioblastoma, one of the most aggressive and treatment-resistant brain cancers. The partnership combines BioArctic̵...
BioArctic schedules August 26 webcast for Q2 2026 report
BioArctic AB announced it will release its second quarter report for the period April to June 2026 on August 26 at 8:00 a.m. CEST. The timing underscores the company’s ongoing communication efforts with the market as it advances its neurodegene...
BioArctic’s Leqembi Royalties Surge on Strong Global Q2 Sales
BioArctic reported that partner Eisai’s Alzheimer’s drug Leqembi generated global sales of JPY 29.3 billion in the second quarter of 2026, translating into royalty income of SEK 179 million for the Swedish biopharma group. This represents...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026